[Renal Dyslipidemia]

Area of Science:

• Nephrology
• Endocrinology
• Cardiovascular Medicine

Background:

• Renal diseases are a primary cause of secondary dyslipidemia.
• Impaired renal function and nephrotic syndrome (NS) significantly alter lipid metabolism.
• Dyslipidemia in renal disease is complex, influenced by primary kidney conditions.

Purpose of the Study:

• To review the mechanisms of dyslipidemia in renal diseases.
• To explore the roles of impaired renal function and NS in lipid metabolism.
• To identify key molecular players like PCSK9 and Angptl4 in renal dyslipidemia.

Main Methods:

• Literature review of studies on renal disease and dyslipidemia.
• Analysis of lipid metabolism alterations in impaired renal function and NS.
• Examination of molecular mechanisms affecting lipoprotein clearance.

Main Results:

• Impaired renal function leads to reduced VLDL clearance and disturbed HDL synthesis, causing uremic dyslipidemia (high TG, IDL-C, small-dense LDL-C; low HDL-C).
• Nephrotic syndrome increases LDL-C and/or TG, with NS-induced hypoalbuminemia enhancing LDL and VLDL production.
• PCSK9 and Angptl4 are identified as key inhibitors of LDL and VLDL clearance, respectively, in NS. HDL maturation is impaired in NS, though HDL-C levels may be preserved.

Conclusions:

• Renal diseases induce distinct dyslipidemias through impaired function and nephrotic syndrome.
• Molecular factors such as PCSK9 and Angptl4 play critical roles in regulating lipoprotein metabolism in renal disease.
• Superimposed dyslipidemias, associated with conditions like diabetic nephropathy or drug treatments, further complicate lipid management in renal patients.